☰

Raquel Aloyz - Publications

Affiliations: 
Department of Medicine McGill University, Montreal, QC, Canada 
Area:
Oncology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

42 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Assouline S, Amrein L, Aloyz R, Banerji V, Caplan S, Owen C, Hasegawa W, Robinson S, Shivakumar S, Prica A, Peters A, Hagerman L, Rodriguez L, Skamene T, Panasci L, et al. IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia & Lymphoma. 1-7. PMID 32154751 DOI: 10.1080/10428194.2020.1734594  0.337
2019 Sharif-Askari B, Doyon D, Paliouras M, Aloyz R. Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes. Scientific Reports. 9: 11069. PMID 31363127 DOI: 10.1038/S41598-019-47305-2  0.337
2019 Galicia-Vázquez G, Aloyz R. Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know? Critical Reviews in Oncology/Hematology. 134: 65-70. PMID 30771875 DOI: 10.1016/J.Critrevonc.2018.12.003  0.304
2019 Sharif-Askari B, Aloyz R, Panasci L. Abstract 300: A new combination therapy to treat metastatic breast cancer Cancer Research. 79: 300-300. DOI: 10.1158/1538-7445.Am2019-300  0.396
2018 Galicia-Vázquez G, Aloyz R. Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes. Frontiers in Oncology. 8: 411. PMID 30319974 DOI: 10.3389/Fonc.2018.00411  0.348
2018 Sharif-Askari B, Amrein L, Aloyz R, Panasci L. PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines. Breast Cancer Research and Treatment. PMID 30039287 DOI: 10.1007/S10549-018-4888-6  0.373
2017 Pinedo-Carpio E, Davidson D, Marignac VLM, Panasci J, Aloyz R. Adaptive metabolic rewiring to chronic SFK inhibition. Oncotarget. 8: 66758-66768. PMID 28977994 DOI: 10.18632/Oncotarget.8146  0.407
2015 Abu-Sanad A, Wang Y, Hasheminasab F, Panasci J, Noë A, Rosca L, Davidson D, Amrein L, Sharif-Askari B, Aloyz R, Panasci L. Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan. Frontiers in Pharmacology. 6: 147. PMID 26257651 DOI: 10.3389/Fphar.2015.00147  0.42
2015 Davidson D, Abu-Sanad A, Wang Y, Hasheminasab F, Panasci J, Aloyz R, Panasci L. Abstract 5327: Simultaneous inhibition of ATR and PARP greatly sensitizes colon cancer cell lines to irinotecan Cancer Research. 75: 5327-5327. DOI: 10.1158/1538-7445.Am2015-5327  0.319
2013 Martinez Marignac VL, Smith S, Toban N, Bazile M, Aloyz R. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming. Oncotarget. 4: 2550-66. PMID 24334291 DOI: 10.18632/Oncotarget.1508  0.357
2013 Martinez-Marignac V, Shawi M, Pinedo-Carpio E, Wang X, Panasci L, Miller W, Pettersson F, Aloyz R. Pharmacological targeting of eIF4E in primary CLL lymphocytes. Blood Cancer Journal. 3: e146. PMID 24036945 DOI: 10.1038/Bcj.2013.43  0.386
2013 Shawi M, Chu TW, Martinez-Marignac V, Yu Y, Gryaznov SM, Johnston JB, Lees-Miller SP, Assouline SE, Autexier C, Aloyz R. Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes. Plos One. 8: e70428. PMID 23922990 DOI: 10.1371/Journal.Pone.0070428  0.321
2013 Davidson D, Amrein L, Panasci L, Aloyz R. Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond. Frontiers in Pharmacology. 4: 5. PMID 23386830 DOI: 10.3389/Fphar.2013.00005  0.377
2013 Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro. International Journal of Cancer. Journal International Du Cancer. 133: 247-52. PMID 23238639 DOI: 10.1002/Ijc.27989  0.381
2013 Davidson D, Wang Y, Aloyz R, Panasci L. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Investigational New Drugs. 31: 461-8. PMID 23054213 DOI: 10.1007/S10637-012-9886-7  0.432
2013 Abu-Sanad A, Davidson D, Wang Y, Pollard J, Aloyz R, Panasci L. Abstract B13: ATR and PARP inhibition enhances topoisomerase I-dependent DNA damage in colon cancer cell lines Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-B13  0.427
2012 Davidson D, Grenier J, Martinez-Marignac V, Amrein L, Shawi M, Tokars M, Aloyz R, Panasci L. Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. Investigational New Drugs. 30: 1736-42. PMID 21567185 DOI: 10.1007/S10637-011-9678-5  0.406
2012 Davidson D, Coulombe Y, Martinez-Marignac VL, Amrein L, Grenier J, Hodkinson K, Masson JY, Aloyz R, Panasci L. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Investigational New Drugs. 30: 1248-56. PMID 21221710 DOI: 10.1007/S10637-010-9626-9  0.38
2012 Davidson D, Wang Y, Aloyz R, Panasci L. Abstract 4692: ABT-888 synergizes treatment of colon cancer cell lines with irinotecan Cancer Research. 72: 4692-4692. DOI: 10.1158/1538-7445.Am2012-4692  0.431
2012 Aloyz R, Rousseau C, Diaz Z, Aguilar-Mahecha A, Basik M, Belanger L, Buchanan M, Camlioglu E, Constantin A, Benlimame N, McNamara S, Diaz Z, Orain M, Przybytkowski E, Spatz A, et al. Abstract B24: De novo and acquired resistance to first-line standard therapy in colorectal cancer: from cell lines to metastatic tumors Clinical Cancer Research. 18: B24-B24. DOI: 10.1158/1078-0432.Mechres-B24  0.345
2011 Sahebjam S, Aloyz R, Pilavdzic D, Brisson M, Ferrario C, Bouganim N, Cohen V, Miller WH, Panasci LC. The role of Ki-67 proliferation index vis-à-vis Oncotype DX. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e11055. PMID 28023425 DOI: 10.1200/Jco.2011.29.15_Suppl.E11055  0.307
2011 Ferrario C, Wong A, Gao T, Bouganim N, Aloyz R, Panasci LC. Trastuzumab and vinorelbine in early stages of HER2-positive breast cancer Journal of Chemotherapy. 23: 32-35. PMID 21482492 DOI: 10.1179/Joc.2011.23.1.32  0.323
2011 Martinez-Marignac VL, Rodrigue A, Davidson D, Couillard M, Al-Moustafa AE, Abramovitz M, Foulkes WD, Masson JY, Aloyz R. The effect of a DNA repair gene on cellular invasiveness: XRCC3 over-expression in breast cancer cells. Plos One. 6: e16394. PMID 21283680 DOI: 10.1371/Journal.Pone.0016394  0.383
2011 Amrein L, Davidson D, Shawi M, Petruccelli LA, Miller WH, Aloyz R, Panasci L. Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy. Leukemia Research. 35: 1080-6. PMID 21281966 DOI: 10.1016/J.Leukres.2011.01.004  0.377
2011 Hebb J, Assouline S, Rousseau C, Desjardins P, Caplan S, Egorin MJ, Amrein L, Aloyz R, Panasci L. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Cancer Chemotherapy and Pharmacology. 68: 643-51. PMID 21120481 DOI: 10.1007/S00280-010-1530-7  0.367
2011 Amrein L, Soulières D, Johnston JB, Aloyz R. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leukemia Research. 35: 99-102. PMID 20573397 DOI: 10.1016/J.Leukres.2010.05.029  0.36
2010 Hollmann A, Aloyz R, Baker K, Dirnhofer S, Owens T, Sladek R, Tzankov A. Vav-1 expression correlates with NFκB activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines. Hematological Oncology. 28: 142-50. PMID 20155735 DOI: 10.1002/Hon.935  0.313
2010 Hollmann CA, Tzankov A, Martínez-Marignac VL, Baker K, Grygorczyk C, Grygorczyk R, Foulkes W, Nadeau J, Dirnhofer S, Aloyz R. Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. Leukemia Research. 34: 585-93. PMID 19758698 DOI: 10.1016/J.Leukres.2009.08.030  0.347
2010 Ferrario C, Charamis H, Oyewole-Eletu S, Mihalcioiu CL, Langleben A, Miller WH, Aloyz R, Panasci LC. Phase Ib study of sorafenib and vinorelbine as first-line treatment in patients with metastatic breast cancer. Journal of Clinical Oncology. 28: 1093-1093. DOI: 10.1200/Jco.2010.28.15_Suppl.1093  0.312
2010 Amrein L, Davidson D, Shawi M, Petruccelli L, Miller W, Aloyz R, Panasci L. Abstract LB-100: Optimal modulation of DNA repair in CLL therapy Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-100  0.378
2010 Shawi M, Amrein L, Gryaznov S, Autexier C, Aloyz R. Abstract 3207: Telomerase inhibition affects fludarabine sensitivity in quiescent primary chronic lymphocytic leukemia lymphocytes Cancer Research. 70: 3207-3207. DOI: 10.1158/1538-7445.Am10-3207  0.377
2009 Ferrario C, Wong A, Bouganim N, Gao T, Aloyz R, Panasci LC. Trastuzumab and vinorelbine (TV) in early stages of breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e11556. PMID 27964098 DOI: 10.1200/Jco.2009.27.15_Suppl.E11556  0.308
2009 Amrein L, Panasci L, Gibson SB, Johnston JB, Soulières D, Aloyz R. Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro. British Journal of Haematology. 147: 396-8. PMID 19758122 DOI: 10.1111/J.1365-2141.2009.07814.X  0.319
2008 Amrein L, Hernandez TA, Ferrario C, Johnston J, Gibson SB, Panasci L, Aloyz R. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. British Journal of Haematology. 143: 698-706. PMID 19062342 DOI: 10.1111/J.1365-2141.2008.07418.X  0.372
2007 Loignon M, Amrein L, Dunn M, Aloyz R. XRCC3 depletion induces spontaneous DNA breaks and p53-dependent cell death. Cell Cycle (Georgetown, Tex.). 6: 606-11. PMID 17351336 DOI: 10.4161/Cc.6.5.3923  0.391
2007 Amrein L, Loignon M, Goulet AC, Dunn M, Jean-Claude B, Aloyz R, Panasci L. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase. The Journal of Pharmacology and Experimental Therapeutics. 321: 848-55. PMID 17351105 DOI: 10.1124/Jpet.106.118356  0.383
2006 Amrein L, Aloyz R, Panasci LC. Inhibition of DNA repair in chronic lymphocytic leukemia: Therapeutic implications Journal of Clinical Oncology. 24: 16513-16513. DOI: 10.1200/Jco.2006.24.18_Suppl.16513  0.358
2005 Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. The Journal of Pharmacology and Experimental Therapeutics. 314: 495-505. PMID 15843498 DOI: 10.1124/Jpet.105.084053  0.386
2002 Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC. DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anti-Cancer Drugs. 13: 511-9. PMID 12045463 DOI: 10.1097/00001813-200206000-00010  0.366
2002 Panasci L, Xu ZY, Bello V, Aloyz R. The role of DNA repair in nitrogen mustard drug resistance. Anti-Cancer Drugs. 13: 211-20. PMID 11984064 DOI: 10.1097/00001813-200203000-00002  0.385
2001 Wang ZM, Chen ZP, Xu ZY, Christodoulopoulos G, Bello V, Mohr G, Aloyz R, Panasci LC. In Vitro Evidence for Homologous Recombinational Repair in Resistance to Melphalan Journal of the National Cancer Institute. 93: 1473-1478. PMID 11584063 DOI: 10.1093/Jnci/93.19.1473  0.367
1996 Slack RS, Belliveau DJ, Rosenberg M, Atwal J, Lochmüller H, Aloyz R, Haghighi A, Lach B, Seth P, Cooper E, Miller FD. Adenovirus-mediated gene transfer of the tumor suppressor, p53, induces apoptosis in postmitotic neurons. The Journal of Cell Biology. 135: 1085-96. PMID 8922388 DOI: 10.1083/Jcb.135.4.1085  0.301
Show low-probability matches.